A 67 year old male at a regular checkup underwent esophagogastroduodenoscopy. On performing esophagogastroduodenoscopy, a lesion about 1.2 cm depressed was noted at the gastric angle. The pathology of the biopsy specimen revealed a well-differentiated adenocarcinoma. On performing an abdominal computed tomography (CT) scan & positron emission tomography-computed tomography (PET-CT) scan, no definite evidence of gastric wall thickening or mass lesion was found. However, lymph node enlargement was found in the left gastric and prepancreatic spaces. This patient underwent laparoscopic assisted distal gastrectomy and D2 lymph node dissection. On final examination, it was found out that the tumor had invaded the mucosal layer. The lymph node was a metastasized large cell neuroendocrine carcinoma with an unknown primary site. The patient refused chemotherapy. He opted to undergo a close followup. At the postoperative month 27, he had a focal hypermetabolic lesion in the left lobe of the liver that suggested metastasis on PET-CT scan. He refused to undergo an operation. He underwent a radiofrequency ablation.
Introduction
Cancer of unknown primary site (CUP) represent a heterogeneous group of metastatic tumors for which a standardized diagnostic work-up fails to identify the site of origin at the time of diagnosis and account for 3~5% of all malignancies.(1) Poorly differentiated large cell neuroendocrine carcinoma (LCNEC) comprise a rare and still seldom reported subset of neuroendocrine tumors.
Here, we present a rare case of LCNEC of unknown primary site, which was detected originally in a lymph node of early gastric cancer.
Case Report
A 67 year old male without any significant past medical history underwent esophagogastroduodenoscopy during a routine check-up. He had no other symptoms. Physical examination was unremarkable and laboratory findings showed no abnormalities. On esophagogastroduodenoscopy, mild atrophic change with intestinal metaplasia was noted at the antrum and body. About 1.2 cm depressed lesion at the angle and about 1.5 cm mildly elevated lesion at the posterior wall of the antrum were noted. The pathology of the biopsy specimen revealed a well differentiated adenocarcinoma.
On abdominal computed tomography (CT) scan, there was no definite evidence of gastric wall thickening or mass lesion. However, a lymph node enlargement was found in the left gastric and prepancreatic spaces. On positron emission tomography-computed tomography (PET-CT) scan, there was no visible hypermetabolic activity of proven gastric malignancy. Hypermetabolic activity, however, was depicted in the prepancreatic area and the left gastric area that implied metastatic lymphadenopathy (Fig. 1 ). The The treatment of a NET with liver metastases includes liver resection, liver transplantation, radiofrequency ablation, hepatic transcatheter arterial embolization, peptide receptor radionuclide therapy, chemotherapy, etc. In our case, the tumor was a single lesion that was located in the lateral segment of the liver, and we planned surgery. For patients with NET liver metastases and unknown primary tumor, surgical exploration effectively identifies and resects occult primary tumors that are often located in the small intestine.
Within the gastrointestinal NET, the small intestine is the most common site. Computed tomography may be useful in detecting mesenteric masses that may result from extension of the primary NET or lymph node metastases with associated fibrosis, suggesting a small-intestine primary tumor. (15) If the patient had undergone surgical exploration, we might have a chance to find a lesion that had not shown on abdominal CT scan. However, the patient did not want surgery, so he had radiofrequency ablation. There was no procedure-associated morbidity. He did not want platinum-based chemotherapy that required hospitalization, so he is being treated with oral fluorouracil based chemotherapy.
